NYSE ARCA | ETF
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| ITCI | Intracellular Th | Healthcare | Drug Manufacturers - Specialty & Generic | 4.45% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 4.41% |
| PRGO | Perrigo Company PLC | Healthcare | Drug Manufacturers - Specialty & Generic | 4.24% |
| OGN | Organon & Co | Healthcare | Drug Manufacturers - General | 4.16% |
| CTLT | Catalent Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 4.11% |
| AXSM | Axsome Therapeutics Inc | Healthcare | Biotechnology | 4.03% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 3.96% |
| VTRS | Viatris Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.9% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 3.87% |
| RPRX | Royalty Pharma Plc | Healthcare | Biotechnology | 3.86% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 3.83% |
| JAZZ | Jazz Pharmaceuticals PLC | Healthcare | Biotechnology | 3.81% |
| ZTS | Zoetis Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.51% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.46% |
| ELAN | Elanco Animal Health | Healthcare | Drug Manufacturers - Specialty & Generic | 3.3% |
| CBAY | Cymabay Therapeu | Healthcare | Biotechnology | 2.88% |
| CORT | Corcept Therapeutics Incorporated | Healthcare | Biotechnology | 2.84% |
| ARVN | Arvinas Inc | Healthcare | Biotechnology | 2.1% |
| AMPH | Amphastar P | Healthcare | Drug Manufacturers - Specialty & Generic | 1.82% |
| SAVA | Cassava Sciences Inc | Healthcare | Biotechnology | 1.78% |
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.